Last $234.26 USD
Change Today -1.54 / -0.65%
Volume 1.5M
AGN On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 2:39 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

allergan inc (AGN) Snapshot

Open
$235.26
Previous Close
$235.80
Day High
$235.65
Day Low
$233.42
52 Week High
03/2/15 - $235.84
52 Week Low
04/8/14 - $115.94
Market Cap
72.2B
Average Volume 10 Days
2.0M
EPS TTM
$6.25
Shares Outstanding
307.6M
EX-Date
02/25/15
P/E TM
37.5x
Dividend
$0.20
Dividend Yield
0.09%
Current Stock Chart for ALLERGAN INC (AGN)

allergan inc (AGN) Details

Allergan, Inc. discovers, develops, and commercializes pharmaceuticals, biologics, medical devices, and over-the-counter products in the Unites States and internationally. It operates through two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including, ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth, other prescription, and over-the-counter skin care products; and urology products. The Medical Devices segment provides a range of medical devices comprising breast implants for augmentation, revision, reconstructive surgery, and tissue expanders; and facial aesthetics products. The company also engages in the research and development of various products in ophthalmology, neuromodulators, migraine, urology, medical dermatology, and medical aesthetics. Allergan, Inc. markets and sells its products primarily through its subsidiaries, independent distributors, and regional sales and marketing organizations to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers, government purchasing agencies, and medical practitioners. The company primarily focuses on eye care professionals, neurologists, physiatrists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, urologists, urogynecologists, and general practitioners. It has collaboration agreements with Molecular Partners AG and Serenity Pharmaceuticals, LLC. Allergan, Inc. was founded in 1948 and is headquartered in Irvine, California.

10,500 Employees
Last Reported Date: 02/19/15
Founded in 1948

allergan inc (AGN) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.4M
President
Total Annual Compensation: $718.6K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $425.5K
Corporate Vice President and President of Nor...
Total Annual Compensation: $550.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $661.8K
Compensation as of Fiscal Year 2014.

allergan inc (AGN) Key Developments

Allergan, Inc. Receives Approval from FDA to Market NATRELLE INSPIRA Round Gel-Filled Breast Implants

Allergan Inc. announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market NATRELLE INSPIRA round gel-filled smooth breast implants. The NATRELLE INSPIRA line is different from other available breast implant styles as it has a higher fill ratio that provides an additional breast shaping option for women undergoing reconstruction, augmentation or revision surgery. The FDA approval of NATRELLE INSPIRA round gel-filled smooth breast implants marks the most recent addition to the broad portfolio of currently available NATRELLE products, which include the NATRELLE 410 anatomically shaped implants, classic round gel implants and saline implants. Allergan’s NATRELLE breast implants offer the large number of round gel breast implants with 243 size options and a variety of projection styles. The comprehensive NATRELLE product line enables plastic surgeons to provide a tailored fit based on a patient’s desired look and her individual size and dimensions.

Allergan Declares Fourth Quarter Dividend, Payable on March 20, 2015

Allergan declared a fourth quarter dividend of $0.05 per share, unchanged from the previous quarter. The dividend is payable on March 20, 2015 to stockholders of record on February 9, 2015.

Allergan Inc. Announces Unaudited Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014

Allergan Inc. announced unaudited consolidated financial results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported revenues of $1,889 million against $1,659.6 million a year ago. Operating income was $626.7 million against $454.8 million a year ago. Non GAAP operating income was $822.6 million against $561.6 million a year ago. Earnings from continuing operations before income taxes was $633.9 million against $441 million a year ago. Non GAAP earnings from continuing operations before income taxes was $814.7 million against $541.8 million a year ago. Earnings from continuing operations was $542.6 million or $1.77 per diluted share against $312.6 million or $1.04 per diluted share a year ago. Non GAAP earnings from continuing operations was $665.9 million or $2.17 per diluted share against $404.9 million or $1.35 per diluted share a year ago. Net earnings attributable to company was $537.2 million or $1.76 per diluted s hare against $312.9 million or $1.04 per diluted share a year ago. Non GAAP net earnings attributable to company was $664 million or $2.17 per diluted share against $405.5 million or $1.35 per diluted share a year ago. For the year, the company reported revenues of $7,237.9 million against $6,300.4 million a year ago. Operating income was $2,009.3 million against $1,809.3 million a year ago. Non GAAP operating income was $2,723.1 million against $2,046.3 million a year ago. Earnings from continuing operations before income taxes was $1,989.3 million against $1,730.8 million a year ago. Non GAAP earnings from continuing operations before income taxes was $2,667 million against $1,960.8 million a year ago. Earnings from continuing operations was $1,532.6 million or $5.03 per diluted share against $1,272.5 million or $4.20 per diluted share a year ago. Non GAAP earnings from continuing operations was $2,026 million or $6.65 per diluted share against $1,442.7 million or $4.77 per diluted share a year ago. Net earnings attributable to company was $1,524.2 million or $5.01 per diluted share against $985.1 million or $3.26 per diluted share a year ago. Non GAAP net earnings attributable to company was $2.021.4 million or $6.65 per diluted share against $1,439.1 million or $4.77 per diluted share a year ago. Operating cash flow after capital expenditures was approximately $1.7 billion.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGN:US $234.43 USD -1.37

AGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $294.12 USD -3.19
Astellas Pharma Inc ¥1,977 JPY +27.00
Boston Scientific Corp $16.77 USD -0.2899
Mylan NV $55.09 USD -2.80
Regeneron Pharmaceuticals Inc $412.20 USD -6.24
View Industry Companies
 

Industry Analysis

AGN

Industry Average

Valuation AGN Industry Range
Price/Earnings 46.3x
Price/Sales 9.6x
Price/Book 9.0x
Price/Cash Flow 42.7x
TEV/Sales 8.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALLERGAN INC, please visit www.allergan.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.